Skip to main content
Sirio Pharma Co., Ltd. logo

Sirio Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 300791 ISIN · CNE100003NB0 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,174 across all filing types
Latest filing 2026-01-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300791

About Sirio Pharma Co., Ltd.

https://www.siriopharma.com

Sirio Pharma Co., Ltd. is a global contract development and manufacturing organization (CDMO) specializing in dietary supplements and nutraceuticals. The company provides comprehensive services encompassing product formulation, manufacturing, and packaging. Its portfolio includes diverse delivery formats such as softgels, gummies, tablets, hard capsules, powders, and oral liquids. Sirio Pharma emphasizes innovation in delivery systems, offering specialized solutions like plant-based softgels and advanced probiotic formulations. The organization adheres to rigorous quality management systems and maintains multiple international certifications to meet global regulatory standards. Serving an international clientele, the company supports health and wellness brands through scalable production capacities and integrated supply chain solutions.

Recent filings

Filing Released Lang Actions
关于调整2025年限制性股票激励计划公司层面业绩考核目标并修订相关文件的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement from a company about adjustments to its 2025 restricted stock incentive plan, including changes to performance assessment targets and related documents. It includes specifics about stock grants, performance criteria, board and committee approvals, and legal opinions. The content focuses on changes to an existing stock incentive plan and the related corporate governance and legal compliance steps. It is not a financial report, earnings release, or regulatory certification. It is an announcement of a management-related corporate action concerning stock incentives and performance targets, which fits best under Board/Management Information (MANG) as it involves board resolutions and management decisions about executive compensation plans.
2026-01-29 Chinese
2026年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is titled "仙乐健康科技股份有限公司 2026 年限制性股票激励计划（草案）" which translates to "Xianle Health Technology Co., Ltd. 2026 Restricted Stock Incentive Plan (Draft)". It extensively details a stock incentive plan including the number of shares, eligibility, grant price, vesting and lock-up periods, performance targets, legal compliance, and governance related to the stock incentive plan. The document is a draft plan for a restricted stock incentive program, which is a form of equity compensation for management and key employees. It is not a financial report, earnings release, or regulatory filing about financial results or corporate governance changes. It is also not a proxy statement or voting results announcement. The content is focused on the stock incentive plan details and its implementation, which fits the category of Remuneration Information (DEF 14A) filings that detail compensation plans for executives and directors. The document length is substantial and contains detailed plan provisions, not just an announcement or summary, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the best classification is Remuneration Information (DEF 14A).
2026-01-29 Chinese
2023年限制性股票激励计划实施考核管理办法（二次修订稿）
Governance Information Classification · 95% confidence The document is titled '2023 年限制性股票激励计划实施考核管理办法（二次修订稿）' which translates to '2023 Restricted Stock Incentive Plan Implementation Assessment Management Measures (Second Revision)'. It details the performance assessment criteria, principles, scope, and procedures related to a restricted stock incentive plan for company executives and key personnel. The content focuses on management policies, performance evaluation, and incentive mechanisms rather than financial results, earnings, or regulatory filings. It is a governance-related document outlining internal rules and incentive plan management. The document length is 3446 characters, which is relatively short and does not contain financial statements or earnings data. It is not an announcement of a report but a policy document. Therefore, the most appropriate classification is Governance Information (CGR).
2026-01-29 Chinese
2025年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2025 annual performance forecast (业绩预告) for the company 仙乐健康科技股份有限公司. It provides estimated net profit figures for the full year 2025 and explanations for the expected decline in profit compared to the previous year. It explicitly states that the forecast has not been audited by an accounting firm and that the detailed audited results will be disclosed in the 2025 annual report. The document is relatively short (1783 characters) and serves as a performance forecast announcement rather than a full financial report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results or forecasts for a period but does not contain full audited financial statements or comprehensive analysis. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements and is a forecast rather than a report. It is not a Regulatory Filing (RNS) because it provides substantive financial forecast data. Therefore, the best classification is Earnings Release (ER).
2026-01-29 Chinese
关于董事会薪酬与考核委员会对公司2026年员工持股计划2026年限制性股票激励计划2023年限制性股票激励计划调整事项及2025年限制性股票激励计划调整事项核查意见的公告
Remuneration Information Classification · 95% confidence The document is an official announcement from the company's Board Remuneration and Assessment Committee regarding the verification opinions on the company's employee stock ownership plan and restricted stock incentive plans for the years 2023, 2025, and 2026. It discusses compliance with relevant laws and regulations, the legitimacy of the plans, and the benefits to the company and shareholders. The document is a formal announcement of the board's opinions and approvals related to remuneration and incentive plans, not the remuneration report itself. It does not contain detailed compensation data or executive pay disclosures but focuses on the approval and verification of stock incentive plans. Therefore, it fits best under Remuneration Information (DEF 14A), which covers reports detailing compensation and incentive plans for executives and directors.
2026-01-29 Chinese
第四届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 18th meeting of the 4th Board of Directors of the company, including approval of employee stock ownership plans, stock incentive plans, and authorization requests to the shareholders' meeting. It includes voting results and references to further shareholder meetings. The content focuses on board decisions and management plans rather than financial results or audit reports. It is not a full annual or interim report, nor a call transcript or earnings release. It is not a simple announcement of a report publication but a substantive board meeting resolution document. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2026-01-29 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.